Movers and SHAKERS
Dyadic International Inc. (DYAI)
Higher Visibility to Emerge after Joining Russell 3000 and 2000
Dyadic International Inc. is a biotechnology company developing a proprietary C1 expression platform to express and manufacture biologic products. The C1 technology is part of a fungi expression system, which utilizes inexpensive substrates yielding a high level of production. Dyadic is currently improving and optimizing the production of biological products in a C1 expression system. The company’s partnership portfolio with pharmaceutical and institutions includes Zapi Project, Israel Institute for Biological Research, Mitsubishi Tanabe Pharma, Sanofi-Aventis covering the production of a diverse range of biologics, such as monoclonal antibodies, bispecific and Fc-fusion proteins. Dyadic also established a sub-licensing agreement with an Australian based drug development and contract manufacturing firm, Luina Bio, to utilize C1 platform for the development and commercialization of biological products to prevent and treat animal diseases. Company’s C1 bioenergy business was sold to Dupond Industrial Biosciences (DuPont) for $75 mm in 2015 granting the company the rights to use C1 platform in biopharma applications.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Joined Russell 2000 and 3000 indices. Dyadic (DYAI) is scheduled to join the U.S. broad-market Russell 3000 and 2000 indices effective after the U.S. market opens on June 29, 2020, following the annual Russell index reconstitution.
What does it mean? The Russell 3000 index represents approximately 98% of the investable US equity market and captures the performance of the largest 3,000 companies in the US, while the Russell 2000 index is a small-cap stock market index that comprehends the smallest 2,000 stocks in the Russell 3000 Index. Russell indices are widely used as benchmarks for...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.